Effect of Sociodemographic Factors, Concomitant Disease States, and Measures Performed in the Emergency Department on Patient Disability in Ischemic Stroke: Retrospective Study from Lebanon

Table 2

Effects of demographics and past medical history on mRS at discharge.

		Two category mRS		value	Three category mRS		value
		0-2	>2		0-3	>3
Gender	Male	31 (50.0%)	13 (36.1%)	0.183	34 (45.3%)	10 (43.5%)	0.867
	Female	31 (50.0%)	23 (63.9%)		41 (54.7%)	13 (56.5%)
Marital status	Married	21 (91.3%)	14 (82.4%)	0.397	28 (90.3%)	7 (77.8%)	0.316
	Divorced/widowed	2 (8.7%)	3 (17.6%)		3 (9.7%)	2 (22.2%)
Hypertension	Yes	45 (72.6%)	28 (77.8%)	0.61	57 (76%)	16 (69.6%)	0.435
	No	15 (24.2%)	6 (16.7%)		16 (21.3%)	5 (21.7%)
	Not documented	2 (3.2%)	2 (5.6%)		2 (2.7%)	2 (8.7%)
Arrhythmia	Yes	14 (22.6%)	20 (55.6%)	0.003	21 (28.0%)	13 (56.5%)	0.017
	No	45 (72.6%)	14 (38.9%)		51 (68%)	8 (34.8%)
	Not documented	3 (4.8%)	2 (5.6%)		3 (4%)	2 (8.7%)
Congestive heart failure	Yes	8 (12.9%)	7 (19.4%)	0.559	11 (14.7%)	4 (17.4%)	0.402
	No	52 (83.9%)	27 (75%)		62 (82.7%)	17 (73.9%)
	Not documented	2 (3.2%)	2 (5.6%)		2 (2.7%)	2 (8.7%)
Angina pectoris	Yes	16 (25.8%)	10 (27.8%)	0.874	20 (26.7%)	6 (26.1%)	0.996
	No	43 (69.4%)	25 (69.4%)		52 (69.3%)	16 (69.6%)
	Not documented	3 (4.8%)	1 (2.8%)		3 (4%)	1 (4.3%)
Percutaneous coronary intervention without stent	Yes	2 (3.2%)	2 (5.6%)	0.763	3 (4%)	1 (4.3%)	0.994
	No	57 (91.9%)	33 (91.7%)		69 (92%)	21 (91.3%)
	Not documented	3 (4.8%)	1 (2.8%)		3 (4%)	1 (4.3%)
Coronary artery bypass graft	Yes	3 (4.8%)	3 (8.3%)	0.706	4 (5.3%)	2 (8.7%)	0.836
	No	56 (90.3%)	32 (88.9%)		68 (90.7%)	20 (87%)
	Not documented	3 (4.8%)	1 (2.8%)		3 (4%)	1 (4.3%)
Peripheral arterial disease	Yes	3 (4.8%)	1 (2.8%)	0.839	3 (4%)	1 (4.3%)	0.943
	No	55 (88.7%)	32 (88.9%)		67 (89.3%)	20 (87%)
	Not documented	4 (6.5%)	3 (8.3%)		5 (6.7%)	2 (8.7%)
Vitamin K antagonist	Yes	8 (12.9%)	10 (27.8%)	0.069	11 (14.7%)	7 (30.4%)	0.186
	No	46 (74.2%)	25 (69.4%)		56 (74.7%)	15 (65.2%)
	Not documented	8 (12.9%)	1 (2.8%)		8 (10.7%)	1 (4.3%)
Antiplatelet therapy aspirin	Yes	24 (38.7%)	17 (47.2%)	0.568	33 (44%)	8 (34.8%)	0.73
	No	29 (46.8%)	16 (44.4%)		33 (44%)	12 (52.2%)
	Not documented	9 (14.5%)	3 (8.3%)		9 (12.0%)	3 (13%)
Lipid lowering therapy	Yes	20 (32.3%)	8 (22.2%)	0.282	25 (33.3%)	3 (13%)	0.151
	No	35 (56.5%)	26 (72.2%)		43 (57.3%)	18 (78.3%)
	Not documented	7 (11.3%)	2 (5.6%)		7 (9.3%)	2 (8.7%)
Beta blockers	Yes	3 (5.6%)	1 (3%)	0.731	3 (4.5%)	1 (5%)	0.534
	No	48 (88.9%)	31 (93.9%)		60 (89.5%)	19 (95%)
	Not documented	3 (5.6%)	1 (3%)		4 (6%)	0 (0%)
Calcium channel blockers	Yes	13 (24.1%)	7 (21.2%)	0.349	19 (28.4%)	1 (5%)	0.046
	No	38 (70.4%)	26 (78.8%)		45 (67.2%)	19 (95%)
	Not documented	3 (5.6%)	0 (0%)		3 (4.5%)	0 (0%)
Angiotensin converting enzyme inhibitors	Yes	18 (33.3%)	12 (36.4%)	0.844	23 (34.3%)	7 (35%)	0.531
	No	33 (61.1%)	20 (60.6%)		40 (59.7%)	13 (65%)
	Not documented	3 (5.6%)	1 (3%)		4 (6%)	0 (0%)
Angiotensin receptor blockers	Yes	5 (9.3%)	3 (9.1%)	0.86	7 (10.4%)	1 (5%)	0.382
	No	46 (85.2%)	29 (87.9%)		56 (83.6%)	19 (95%)
	Not documented	3 (5.6%)	1 (3%)		4 (6%)	0 (0%)